# Clostridium difficile-associated Disease (CdAD),

# Infection Control and Fecal Management

#### Phil Bowler, MPhil, BSc ConvaTec Wound Therapeutics, Deeside, UK

2008 E.R. Squibb & Sons, L.L.C.

Flexi-Seal is a registered trademark of E.R. Squibb & Sons, L.L.C. ConvaTec is an authorised user.

### Clostridium difficile (C. diff)





Reproduced with kind permission from Dr Jan Hobot, Director of Medical Microscopy Sciences, School of Medicine, Cardiff University, UK

20 ETDU ligh vacuum

# Fecal Incontinence (FI) and the Flexi-Seal<sup>®</sup> Fecal Management System (FMS)

- FI is associated with skin breakdown, excoriation, cross infection and loss of comfort for the patient
- Current methods of managing FI include disposable absorbent pads, diapers, rectal tubes and faecal collection pouches
  - Can lead to extended hospital stay due to skin breakdown, perineal wounds, damage to rectal mucosa and infection
- Flexi-Seal<sup>®</sup> FMS is designed for the diversion & containment of faecal effluent in immobilised patients with episodic FI
  - Consists of a soft silicone catheter, an inflatable retention balloon and a collection bag

#### Flexi-Seal<sup>®</sup> FMS





# In Vitro Study to Investigate the C. diff Containment Properties of Flexi-Seal® FMS

- Flexi-Seal<sup>®</sup> FMS compared against a standard disposable absorbent under pad
- A clinical wound isolate of *C. diff* used in the study
- A semi-solid agar medium (reinforced clostridial medium) was used to simulate faecal effluent in CdAD patients
- The Flexi-Seal<sup>®</sup> FMS study was conducted over 31 days (maximum intended use is 29 consecutive days)
- Swabbing of the device, environmental settle plates and air count techniques were used to assess transmission of *C.diff* through the Flexi-Seal<sup>®</sup> FMS and into the surrounding environment
- Swab samples were taken daily

# In Vitro Study to Investigate the C. diff Containment Properties of Flexi-Seal® FMS

- Four tests were conducted with the Flexi-Seal<sup>®</sup> FMS device, and a positive control was also included (i.e. a Flexi-Seal<sup>®</sup> FMS device which was purposely pierced with a sterile needle at various positions along the device)
- The disposable absorbent under-pad was tested using a standard ConvaTec method for testing the bacterial barrier properties of wound dressings (5-day test)

#### Flexi-Seal<sup>®</sup> FMS *In Vitro* Methodology: Set-up



# Flexi-Seal<sup>®</sup> FMS *In Vitro* Methodology: Sampling



# Testing of Disposable Absorbent Under-pads



# Culture & Identification of C. diff



#### Results

- No detection of *C. diff* spores on the outer side of the Flexi-Seal<sup>®</sup>
  FMS (n = 4)
  - No evidence of *C. diff* in the surrounding environment (environmental settle plates and air counts)
- C. diff spores were consistently detected from the positive Flexi-Seal<sup>®</sup>
  FMS control device
  - Evidence of *C. diff* on environmental settle plates in the vicinity of the positive control
- There was no evidence of transmission of *C. diff* through the absorbent under-pad; however the *C. diff* fluid suspension wicked across the absorbent surface of the under-pad

#### Summary & Conclusion

- A stringent *in vitro* model designed to simulate and monitor containment of faecal effluent and *C. diff* in a CdAD patient demonstrated that:
  - The Flexi-Seal® FMS effectively contained C. diff
  - The Flexi-Seal<sup>®</sup> FMS was not associated with environmental contamination with *C. diff* in the vicinity of the collection system
  - Based on *in vitro* data, the Flexi-Seal<sup>®</sup> FMS device effectively contains *C. diff* and should consequently be considered as part of an infection control strategy in the management of CdAD patients

### The Team



CA-08-1301